Cystic lymphangioma treatment drug

1 . A method for treating cystic lymphangioma comprising administering to a subject in need thereof an effective amount of an agent as an active ingredient (i) that causes suppression of expression of amphiregulin, suppression of secretion of amphiregulin, and/or inhibition of binding of amphiregulin with an amphiregulin receptor, or (ii) that causes suppression of expression of an amphiregulin receptor, suppression of activation of an amphiregulin receptor, and/or inhibition of binding of an amphiregulin receptor with amphiregulin.

2 . The method according to claim 1 , wherein the agent is selected from the group consisting of a neutralizing antibody against amphiregulin, an antigen binding fragment of a neutralizing antibody against amphiregulin.

3 . The method according to claim 1 , wherein the agent is selected from the group consisting of a neutralizing antibody against an amphiregulin receptor, an antigen binding fragment of a neutralizing antibody against an amphiregulin receptor, and an EGFR tyrosine kinase inhibitor.

4 . A method for testing cystic lymphangioma comprising

collecting a sample from a subject,

measuring amphiregulin or an amphiregulin receptor in the sample by using a test agent, and

treating the subject,

wherein the treatment is selected from the group consisting of administration of a medicinal agent, exercise therapy, and dietary therapy, and

wherein the test agent comprises either substance of (a) or (b):

(a) a substance that binds amphiregulin selected from the group consisting of a neutralizing antibody against amphiregulin, an antigen binding fragment of a neutralizing antibody against amphiregulin and an aptamer against amphiregulin, a substance that binds DNA encoding amphiregulin, a substance that binds mRNA transcribed based on DNA encoding amphiregulin as a template, and cDNA reverse-transcribed based on amphiregulin mRNA as a template; and

(b) a substance that binds an amphiregulin receptor selected from the group consisting of a neutralizing antibody against an amphiregulin receptor, an antigen binding fragment of a neutralizing antibody against an amphiregulin receptor and an aptamer against an amphiregulin receptor, a substance that binds DNA encoding an amphiregulin receptor, a substance that binds mRNA transcribed based on DNA encoding an amphiregulin receptor as a template, and cDNA reverse-transcribed based on amphiregulin receptor mRNA as a template.

5 . A method for determining cystic lymphangioma comprising

collecting a sample from a subject,

measuring a level of amphiregulin or an amphiregulin receptor in the sample by using a test agent,

determining that when the level of amphiregulin or an amphiregulin receptor in a sample collected from a subject is the same as or lower than the level of amphiregulin or an amphiregulin receptor in a sample collected from a normal subject, it means that the possibility of incidence of cystic lymphangioma is low in the subject,

or that the level of amphiregulin in a sample collected from a subject is the same as or higher than the average value or the middle value of the level of amphiregulin in samples collected from patients with cystic lymphangioma or a cutoff value that distinguishes between the level of amphiregulin in samples collected from patients with cystic lymphangioma and the level of amphiregulin in samples collected from normal subjects, it means that the possibility of incidence of cystic lymphangioma is high in the subject, and

treating the subject

wherein the treatment is selected from the group consisting of administration of a medicinal agent, exercise therapy, and dietary therapy, and

wherein the test agent comprises either substance of (a) or (b):

(a) a substance that binds amphiregulin selected from the group consisting of a neutralizing antibody against amphiregulin, an antigen binding fragment of a neutralizing antibody against amphiregulin and an aptamer against amphiregulin, a substance that binds DNA encoding amphiregulin, a substance that binds mRNA transcribed based on DNA encoding amphiregulin as a template, and cDNA reverse-transcribed based on amphiregulin mRNA as a template; and

(b) a substance that binds an amphiregulin receptor selected from the group consisting of a neutralizing antibody against an amphiregulin receptor, an antigen binding fragment of a neutralizing antibody against an amphiregulin receptor and an aptamer against an amphiregulin receptor, a substance that binds DNA encoding an amphiregulin receptor, a substance that binds mRNA transcribed based on DNA encoding an amphiregulin receptor as a template, and cDNA reverse-transcribed based on amphiregulin receptor mRNA as a template.